stellar strong outlookpo
ticker handili beat expect show impress
acceler tougher comp global revenu grew came better
street vs street us busi grew y/i ou
revenu bounc back grow sequenti revenu absolut
dollar last year all-tim high us growth
fastest year busi third size street
current model high-teen revenu growth look increasingli
conserv given tailwind next year adopt cgm appear
slow even type popul cgm use could doubl current
penetr see prefer co pay statu larg payer go
effect launch patient medicar opportun time
gap libr continu shrink result result
increas confid outlook rais po ev/
sale ev/ reiter buy rate
progress profit
path real margin becom evid sg
grow vs revenu growth first three quarter year
sg revenu grown faster expect end
oper margin almost doubl origin expect
manag price headwind gross margin expect
slightli lower previou expect sole due
challeng late third quarter one autom sensor product
line temporarili lower product level lower cost transmitt track
still posit gross margin
net dbt
rais po
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
dexcom inc oper medic devic
compani focus design develop
continu glucos monitor cgm system
peopl diabet compani
develop small implant devic
continu measur glucos level
subcutan tissu skin real-tim
data process display patient
also alert level high low
product market physician
endocrinologist diabet educ
see sever avenu beat street
estim launch medicar
conserv assumpt util price
competit could drive upsid near term
long-term penetr non-intens type
increas total avail market opportun
also believ cgm remain top-tier
growth market patient adopt cgm
beneficiari tailwind
valu ev/sal given compani trade revenu growth
price object base revenu estim multipl line
small mid-cap med-tech compani similar revenu growth rate
market opportun
upsid risk strateg activ patient expect less impact
expect competit faster approv pipelin product
downsid risk price pressur fewer patient added/high attrit current
patient due competitor threat lack patient want adopt cgm delay
pipelin product
travi steed herebi certifi view express research report accur
reflect person view subject secur issuer also certifi
part compens directli indirectli relat specif
recommend view express research report
becton dickinson compani
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
